New study below [1].
"Among 13 065 men, 2976 were diagnosed with PCa over median follow‐up of 6.6 years.
"Statin use was associated with lower risk of both Gleason low‐ (score <7: aHR {adjusted hazard ratios}, 0.85 ...) and high‐grade PCa (score ≥7: aHR, 0.54 ..).
"The protective association was observed only when statins had been used for a relatively longer duration (≥11 months) or higher dose (≥121 defined daily doses)"
Protection was "more pronounced for PCa of higher Gleason score":
<7: aHR, 0.85
7 [3 + 4]: aHR, 0.62
7 [4 + 3]: aHR, 0.49
8: aHR, 0.60
9‐10: aHR, 0.24
"Lipophilic statins (aHR, 0.83 ...) might be more protective than hydrophilic statins (aHR, 0.91 ...) against PCa."
-Patrick
[1] onlinelibrary.wiley.com/doi...
Full text: onlinelibrary.wiley.com/doi...
Association of statin use with risk of Gleason score‐specific prostate cancer: A hospital‐based cohort study
Kai Wang Travis A. Gerke Xinguang Chen Mattia Prosperi
First published: 08 October 2019
Funding information:
None.
Abstract
Background
Conflicting evidence suggests that statins act chemopreventively against prostate cancer (PCa). Whether the association of statin use with PCa risk is Gleason score‐dependent, time‐, dose‐respondent is not well studied.
Methods
We conducted a cohort study at a tertiary hospital in the Southeastern US using longitudinal data of electronic medical records (EMR) from 1994 to 2016. Only cancer‐free men aged >18 years at baseline with follow‐up time of ≥12 months were included. Time‐dependent Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs).
Results
Among 13 065 men, 2976 were diagnosed with PCa over median follow‐up of 6.6 years. Statin use was associated with lower risk of both Gleason low‐ (score <7: aHR, 0.85; 95% CI, 0.74‐0.96) and high‐grade PCa (score ≥7: aHR, 0.54; 95% CI, 0.42‐0.69). The protective association was observed only when statins had been used for a relatively longer duration (≥11 months) or higher dose (≥121 defined daily doses), and were more pronounced for PCa of higher Gleason score (<7: aHR, 0.85, 95% CI, 0.74‐0.96; 7 [3 + 4]: aHR, 0.62, 95% CI, 0.43‐0.90; 7 [4 + 3]: aHR, 0.49, 95% CI, 0.29‐0.82; 8: aHR, 0.60, 95% CI, 0.37‐0.96; 9‐10: aHR, 0.24, 95% CI, 0.11‐0.54). Lipophilic statins (aHR, 0.83; 95% CI, 0.72‐0.95) might be more protective than hydrophilic statins (aHR, 0.91, 95% CI, 0.63‐1.33) against PCa.
Conclusion
Statin use might be associated with reduced PCa risk only when used for a relatively longer duration, and the risk reduction was higher for PCa of higher Gleason score.